397864-44-7 Usage
Description
Different sources of media describe the Description of 397864-44-7 differently. You can refer to the following data:
1. Fluticasone furoate is a new corticosteroid derivative launched as a
nasal spray for the treatment of seasonal and perennial allergic rhinitis in adults
and in children aged ≥2 years. It is structurally closely related to the previously
marketed intranasal corticosteroid fluticasone propionate (FP). Both of these
steroids contain the unusual S-fluoromethyl carbothioate group, which confers
high lipophilicity and hence enhanced binding and retention of the drug by the
nasal tissue. Additionally, the carbothioate group rapidly undergoes first-pass
metabolism by CYP3A4, thus minimizing systemic exposure of the parent drug.
Fluticasone furoate is a potent ligand for the glucocorticoid receptor (GR), with
a relative receptor affinity (RRA) of 2,989 with reference to dexamethasone RRA
of 100. Following intranasal administration, most of the dose is eventually swallowed and undergoes incomplete absorption and extensive firstpass metabolism in the liver and gut, resulting in negligible systemic exposure. Pharmacokinetic studies using oral solution dosing and intravenous dosing show that at least 30% of fluticasone furoate is absorbed and then rapidly cleared from plasma. The most common adverse reactions (W1% incidence) included headache, epistatix, sinus and throat pain, nasal ulceration, back pain, pyrexia, and cough. Fluticasone furoate is chemically derived starting from a readily available corticosteroid, 6a,9a-difluoro-11b,17a-dihydroxy-16a-methyl-3-oxoandrosta-1,4-diene-17b-carboxylic acid, by first converting the carboxylic acid group to the corresponding carbothioic acid via activation with carbonyl diimidazole followed by reaction with hydrogen sulfide gas. Subsequently, selective acylation of the 17a-hydroxyl group with 2-furoyl chloride and alkylation of the 17b-carbothioic acid group with bromofluoromethane under basic conditions provides fluticasone furoate.
2. Fluticasone furoate is a synthetic glucocorticoid. It is selective for the glucocorticoid receptor over the mineralocorticoid, progesterone, and androgen receptors in reporter assays (EC50s = 0.03, 23.4, 0.9, and >10,000 nM, respectively), as well as estrogen receptor α (ERα) and ERβ in scintillation proximity assays (EC50s = >10,000 nM for both). Fluticasone furoate reduces LPS-induced increases in TNF-α production in human peripheral blood mononuclear cells (PBMCs) with an EC50 value of 0.12 nM. It decreases S. aureus enterotoxin-induced increases in IFN-γ, IL-2, IL-5, IL-17, and TNF-α levels in patient-derived nasal polyp tissue when used at a concentration of 100 nM. Intrathecal administration of fluticasone furoate (30 μg/animal) reduces ovalbumin-induced increases in bronchoalveolar lavage fluid (BALF) eosinophil infiltration in a rat model of allergic inflammation. Formulations containing fluticasone furoate have been used in the treatment of seasonal allergies.
Chemical Properties
White to Off-White Solid
Uses
Different sources of media describe the Uses of 397864-44-7 differently. You can refer to the following data:
1. It is one of the newest
2. A synthetic corticosteroid
3. Fluticasone-d3 Furoate is an isotope labelled form of Fluticasone Furoate (F599510). Fluticasone Furoate is a synthetic corticosteroid derived from fluticasone for treatment of seasonal allergic rhinitis.
Definition
ChEBI: A trifluorinated corticosteroid that consists of 6alpha,9-difluoro-11beta,17alpha-dihydroxy-17beta-{[(fluoromethyl)sulfanyl]carbonyl}-16-methyl-3-oxoandrosta-1,4-diene bearing a 2-furoyl s
bstituent at position 17. Used in combination with vilanterol trifenate for treatment of bronchospasm associated with chronic obstructive pulmonary disease.
Brand name
Veramyst
Synthesis
The synthesis of fluticasone on large scale was
disclosed in the patent literature. The starting 6α ,9α-
difluoro-11β-17α-dihydroxy-16α-methyl-3-oxoandrosta-1,4-
diene-17β-carboxylic acid 35 was converted to the
analogous carbothioic acid 36 in 95% yield via activation
with carbonyl diimidazole, followed by reaction with hydrogen
sulfide gas. Conversion of the carbothioic
acid to fluticasone was completed through a three-step sequence
in a one pot process in 99% overall yield. Carbothioic
acid 36 and DMAP were dissolved in MEK. Tripropylamine
(TPA) was then added to the mixture at -8 to -5°C.
Neat furoyl chloride was then added dropwise over 2-3 minutes
and the resulting mixture was then stirred at -5 to 0°C
for 15 minutes generating a mixture of desired ester 37 and
thioanhydride 38. A solution of N-methylpiperazine in water
was then added dropwise over 2-3 minutes at -5 to 0°C to the crude reaction mixture and stirred for 10 minutes, which
enabled the conversion of thioanhydride 38 to the ester 37. A
solution of bromofluoromethane in MEK was then added
rapidly at 0°C and the resulting solution was stirred at 20°C
for 5 hours. After a simple work-up, fluticasone furoate (V)
was obtained in 99% overall yield from 36 with 97% purity.
Check Digit Verification of cas no
The CAS Registry Mumber 397864-44-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,9,7,8,6 and 4 respectively; the second part has 2 digits, 4 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 397864-44:
(8*3)+(7*9)+(6*7)+(5*8)+(4*6)+(3*4)+(2*4)+(1*4)=217
217 % 10 = 7
So 397864-44-7 is a valid CAS Registry Number.
397864-44-7Relevant articles and documents
X-ray crystal structure of the novel enhanced-affinity glucocorticoid agonist fluticasone furoate in the glucocorticoid receptor-ligand binding domain
Biggadike, Keith,Bledsoe, Randy K.,Hassell, Anne M.,Kirk, Barrie E.,McLay, Iain M.,Shewchuk, Lisa M.,Stewart, Eugene L.
, p. 3349 - 3352 (2008)
An X-ray crystal structure is reported for the novel enhanced-affinity glucocorticoid agonist fluticasone furoate (FF) in the ligand binding domain of the glucocorticoid receptor. Comparison of this structure with those of dexamethasone and fluticasone pr
Preparation method of fluticasone furoate
-
Paragraph 0059; 0060; 0061; 0062; 0063, (2017/04/29)
The invention relates to a preparation method of fluticasone furoate, especially preparation and purification of an intermediate 6alpha, 9alpha-difluoro-17alpha-[(2-furylcarbonyl)oxy]-11beta-hydroxy-16alpha-methyl-3-oxo-androstane-1,4-diene-17beta-thiocarboxylic acid. The preparation method comprises the following steps: in the presence of alkali and alcoholic solvent, a compound as shown in the formula VIII is converted into a mixture containing the compound of formula II; the mixture containing the compound of formula II is mixed with an aqueous solution of inorganic base and an ester solvent; a water phase is separated; pH value of the water phase is regulated by the use of acid until a solid is precipitated out; and the solid is separated. The invention provides a preparation method capable of remarkably raising purity of fluticasone furoate. Safety of drug application is guaranteed.
PROCESS FOR PREPARING FLUTICASONE PROPIONATE/FUROATE
-
Paragraph 0066, (2014/06/11)
The present invention relates to an improved process for the preparation of substituted Fluticasone derivatives. The invention also reveals the processes for the purification of Fluticasones and related intermediates to provide the highly pure product.
